The drug Eliquis (apixaban) is a new anticoagulant option that is at least as effective as other current blood thinners and possibly better at reducing rates of major bleeding, according to a recent trial. Eliquis, an oral direct Factor Xa inhibitor developed by Bristol-Myers Squibb (NYSE: BMY) and Pfizer Inc. (NYSE: PFE), was recently used in a six-month AMPLIFY trial. By inhibiting a key protein that clots blood, Eliquis prevents thrombin and blood clot formation. Acute venous thromboembolism (VTE) is a blood clot that forms within a vein, usually in the leg...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment